-
1
-
-
0033945012
-
Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study
-
Hilleman DE, Heineman SM, Ford PA. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. Pharmacotherapy 2000;20:819-22.
-
(2000)
Pharmacotherapy
, vol.20
, pp. 819-822
-
-
Hilleman, D.E.1
Heineman, S.M.2
Ford, P.A.3
-
2
-
-
0032032592
-
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
-
Jones PH, Kafonek S, Lauora I, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
-
(1998)
Am J Cardiol
, vol.81
, pp. 582-587
-
-
Jones, P.H.1
Kafonek, S.2
Lauora, I.3
-
3
-
-
0038645309
-
Comparison of atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial)
-
Jones PH, Davidson MH, Stein EA, et al. Comparison of atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003;92:152-60.
-
(2003)
Am J Cardiol
, vol.92
, pp. 152-160
-
-
Jones, P.H.1
Davidson, M.H.2
Stein, E.A.3
-
5
-
-
0035897696
-
Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
-
(2001)
JAMA
, vol.285
, pp. 2486-2497
-
-
-
6
-
-
0032189666
-
Prevention of coronary heart disease in clinical practice: Recommendations of the second joint task force of European and other societies on coronary prevention
-
Wood D, De Backer G, Faegeman O, Graham I, Mancia G, Pyorola K. Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies on coronary prevention. Eur J Heart 1998;19:1434-503.
-
(1998)
Eur J Heart
, vol.19
, pp. 1434-1503
-
-
Wood, D.1
De Backer, G.2
Faegeman, O.3
Graham, I.4
Mancia, G.5
Pyorola, K.6
-
7
-
-
0030603188
-
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era
-
Jacobson, TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol 1996;78(suppl 6A):32-41.
-
(1996)
Am J Cardiol
, vol.78
, Issue.SUPPL. 6A
, pp. 32-41
-
-
Jacobson, T.A.1
-
8
-
-
0032563770
-
Economic implications of lipid-lowering trials: Current considerations in selecting a statin
-
Farmer JA. Economic implications of lipid-lowering trials: current considerations in selecting a statin. Am J Cardiol 1998;82:26-31M.
-
(1998)
Am J Cardiol
, vol.82
-
-
Farmer, J.A.1
-
9
-
-
1542437305
-
Determinants of the cost-effectiveness of statins
-
Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm 2003;9:544-51.
-
(2003)
J Manag Care Pharm
, vol.9
, pp. 544-551
-
-
Morrison, A.1
Glassberg, H.2
-
10
-
-
0027243348
-
Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
-
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993;269:3015-23.
-
(1993)
JAMA
, vol.269
, pp. 3015-3023
-
-
-
11
-
-
0034723758
-
The lipid-treatment assessment project (L-TAP): A multicenter survey to evaluate the percentage of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol levels
-
Pearson TA, Laurora I, Chu H, Kafonek S. The lipid-treatment assessment project (L-TAP): a multicenter survey to evaluate the percentage of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol levels. Arch Intern Med 2000;160:459-67.
-
(2000)
Arch Intern Med
, vol.160
, pp. 459-467
-
-
Pearson, T.A.1
Laurora, I.2
Chu, H.3
Kafonek, S.4
-
12
-
-
0035897079
-
Assessing the results: Phase I hyperlipidemic outcomes in 27 health plans
-
Latts LM. Assessing the results: phase I hyperlipidemic outcomes in 27 health plans. AmJ Med 2001;110(suppl 6A):17S-23.
-
(2001)
AmJ Med
, vol.110
, Issue.SUPPL. 6A
-
-
Latts, L.M.1
-
13
-
-
0027154796
-
Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the national cholesterol education program adult treatment panel
-
Sempos CT, Cleeman JI, Carroll MD, et al. Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the national cholesterol education program adult treatment panel. JAMA 1993;269:3009-14.
-
(1993)
JAMA
, vol.269
, pp. 3009-3014
-
-
Sempos, C.T.1
Cleeman, J.I.2
Carroll, M.D.3
-
14
-
-
0037031061
-
MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
-
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
-
(2002)
Lancet
, vol.360
, pp. 7-22
-
-
-
15
-
-
0037420492
-
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): A multicentre randomised controlled trial
-
Sever PS, Dahlof B, Poulter NR, et al, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
-
(2003)
Lancet
, vol.361
, pp. 1149-1158
-
-
Sever, P.S.1
Dahlof, B.2
Poulter, N.R.3
-
16
-
-
11144355354
-
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
-
Cannon CP, Braunwald E, McCabe CH, et al, for the PROVE IT-TIMI 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
-
(2004)
N Engl J Med
, vol.350
, pp. 1495-1504
-
-
Cannon, C.P.1
Braunwald, E.2
McCabe, C.H.3
-
17
-
-
10744225301
-
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial
-
Nissen SE, Tuzeu EM, Schoenhagen P, et al, for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
-
(2004)
JAMA
, vol.291
, pp. 1071-1080
-
-
Nissen, S.E.1
Tuzeu, E.M.2
Schoenhagen, P.3
-
18
-
-
3142729178
-
Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines
-
Grundy SM, Cleeman JI, Merz CNB, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
-
(2004)
Circulation
, vol.110
, pp. 227-239
-
-
Grundy, S.M.1
Cleeman, J.I.2
Merz, C.N.B.3
-
19
-
-
0242285687
-
The statin wars: Why AstraZeneca must retreat
-
Anonymous. The statin wars: why AstraZeneca must retreat [editorial]. Lancet 2003;362:1341.
-
(2003)
Lancet
, vol.362
, pp. 1341
-
-
-
20
-
-
0242361274
-
The statin wars
-
McKillop T. The statin wars [letter]. Lancet 2003;362:1498.
-
(2003)
Lancet
, vol.362
, pp. 1498
-
-
McKillop, T.1
-
21
-
-
0344688166
-
The statin wars
-
Dunselman P, Hjalmarson A, Kjekshus J, McMurray J, Waagstein F, for the Executive Committee of the CORONA trial. The statin wars [letter]. Lancet 2003;362:1854.
-
(2003)
Lancet
, vol.362
, pp. 1854
-
-
Dunselman, P.1
Hjalmarson, A.2
Kjekshus, J.3
McMurray, J.4
Waagstein, F.5
-
22
-
-
1542572131
-
The statin wars
-
Olsson GO, Blasetto JW, Bryzinski BS, Caplan RJ, Gold A. The statin wars [letter]. Lancet 2003;362:1855-6.
-
(2003)
Lancet
, vol.362
, pp. 1855-1856
-
-
Olsson, G.O.1
Blasetto, J.W.2
Bryzinski, B.S.3
Caplan, R.J.4
Gold, A.5
-
25
-
-
0032842443
-
Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy: An illustrative example focusing on the primary prevention of coronary heart disease in Canada
-
Morris S, Godber E. Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy: an illustrative example focusing on the primary prevention of coronary heart disease in Canada. Pharmacoeconomics 1999;16:193-205.
-
(1999)
Pharmacoeconomics
, vol.16
, pp. 193-205
-
-
Morris, S.1
Godber, E.2
-
26
-
-
0036915307
-
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia
-
Olsson AG, Istad H, Luurila O, et al, for the Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51.
-
(2002)
Am Heart J
, vol.144
, pp. 1044-1051
-
-
Olsson, A.G.1
Istad, H.2
Luurila, O.3
-
27
-
-
0036910821
-
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial
-
Brown WV, Bays HE, Hassman DR, et al, for the Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43.
-
(2002)
Am Heart J
, vol.144
, pp. 1036-1043
-
-
Brown, W.V.1
Bays, H.E.2
Hassman, D.R.3
|